EPHB4是急性髓系白血病的治疗靶点并通过AKT促进白血病细胞存活
本文显示EPHB4在约30%的急性髓系白血病(AML)样本中高表达,无偏倚RNA干扰筛选发现EPHB4驱动部分AML病例的存活,敲低EPHB4抑制磷脂酰肌醇3-激酶/AKT信号并降低细胞活力,该效应可被组成性激活的AKT挽救,用高特异性单克隆抗体MAb131靶向EPHB4在体外和体内均对AML有效,因此EPHB4是EPHB4高表达AML的潜在靶点。
要点
- EPHB4在约30%的AML样本中高表达。
- 敲低EPHB4抑制PI3K/AKT信号并降低细胞活力,可被组成性激活的AKT挽救。
- 高特异性单克隆抗体MAb131靶向EPHB4在体外和体内均对AML有效。
核心结论
- EPHB4是EPHB4高表达AML的潜在靶点。
研究设计与样本
- 研究对原代白血病样本进行无偏倚RNA干扰筛选,并在体外和体内评估靶向EPHB4的效果。
主要发现
- EPHB4在约30%的急性髓系白血病(AML)样本中高表达。
- 无偏倚RNA干扰筛选发现EPHB4驱动部分AML病例的存活。
- 敲低EPHB4抑制磷脂酰肌醇3-激酶/AKT信号,并伴随细胞活力降低,该降低可被组成性激活的AKT挽救。
- 用高特异性单克隆抗体MAb131靶向EPHB4在体外和体内均对AML有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and is a promising target in cancer therapy; however, little is known about its role in hematologic malignancies. In this article, we show that EPHB4 is highly expressed in ∼30% of acute myeloid leukemia (AML) samples. In an unbiased RNA interference screen of primary leukemia samples, we found that EPHB4 drives survival in a subset of AML cases. Knockdown of EPHB4 inhibits phosphatidylinositol 3-kinase/AKT signaling, and this is accompanied by a reduction in cell viability, which can be rescued by a constitutively active form of AKT. Finally, targeting EPHB4 with a highly specific monoclonal antibody (MAb131) is effective against AML in vitro and in vivo. EPHB4 is therefore a potential target in AML with high EPHB4 expression.
引用
- Merchant AA, Jorapur A, McManus A, et al. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Adv. 2017. PMID: 29296810. doi:10.1182/bloodadvances.2017005694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。